 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 905187
Online Users : 915
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/13797
|
| Title: | The impact of urate-lowering therapy in post-myocardial infarction patients: Insights from a population-based, propensity score-matched analysis |
| Authors: | Tai, CJ;Wu, CC;Lee, KT;Tseng, TG;Wang, HC;Chang, FR;Yang, YH |
| Contributors: | National Institute of Cancer Research |
| Abstract: | The role of urate-lowering therapy (ULT) for the primary prevention of cardiovascular events has been widely discussed, but its evidence for the secondary prevention of myocardial infarction (MI) is limited. Therefore, we conduct a population-based, propensity score-matched cohort study to investigate the cardiovascular outcomes among post-MI patients with and without ULT. A total of 19,042 newly diagnosed in-hospital MI patients were selected using the Taiwan National Health Insurance Database between 1 January 2005 and 31 December 2016. After 1:1 propensity score matching with covariates, MI patients with (n=963) and without (n=963) ULT were selected for further analysis. The primary outcome was the all-cause mortality and the secondary outcomes were composite cardiovascular (CV) outcomes, including hospitalization for recurrent MI, stroke, heart failure, and cardiac arrhythmias. ULT users were associated with lower all-cause mortality (adjusted hazard ratio [adjHR], 0.67; 95% confidence interval [CI], 0.51-0.87) compared to the ULT nonusers. In addition, ULT users had a significantly lower risk of recurrent MI which needed revascularization by percutaneous coronary intervention or coronary artery bypass grafting (adjHR, 0.67; 95% CI, 0.53-0.86) than the ULT nonusers. The primary and secondary outcomes were not different between post-MI patients who received uricosuric agents and xanthine oxidase inhibitors. The anti-inflammatory effect of ULT plays an essential role in MI management. From a real-world setting, this study shows that ULT is associated with the lower risk of all-cause mortality in post-MI patients. In addition, the result shows the possible lower incidence of repeat revascularization procedures in the ULT users. |
| Date: | 2022-03 |
| Relation: | Clinical Pharmacology and Therapeutics. 2022 Mar;111(3):655-663. |
| Link to: | http://dx.doi.org/10.1002/cpt.2473 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0009-9236&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000719365500001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85119085105 |
| Appears in Collections: | [楊奕馨] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB34719019.pdf | | 13645Kb | Adobe PDF | 220 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
